A genotype of modified vaccinia Ankara (MVA) that facilitates replication in suspension cultures in chemically defined medium

Viruses

Volumn 5, Issue 1, 2013, Pages 321-339

  Jordan, Ingo ^a   Horn, Deborah ^a   John, Katrin ^a   Sandig, Volker ^a  

^a PROBIOGEN AG   (Germany)

Author keywords

AGE1.CR.pIX; Duck suspension cell line; Modified vaccinia Ankara; MVA; Vaccine

Indexed keywords

A34R PROTEIN; A3L PROTEIN; A9L PROTEIN; ASPARTIC ACID; GLUTAMIC ACID; HISTIDINE; LYSINE; TYROSINE; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PROTEIN;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CELL FREE SYSTEM; CONTROLLED STUDY; DNA DETERMINATION; DNA SEQUENCE; GENETIC STABILITY; GENETIC VARIABILITY; GENOTYPE; HOST RESISTANCE; MODIFIED VACCINIA ANKARA; NEW SPECIES; NONHUMAN; NUCLEOTIDE SEQUENCE; PROCESS DEVELOPMENT; SEQUENCE ANALYSIS; SUPERNATANT; VACCINIA VIRUS; VIRUS CULTURE; VIRUS ENTRY; VIRUS GENOME; VIRUS INFECTIVITY; VIRUS REPLICATION;

EID: 84872861070     PISSN: 19994915     EISSN: None     Source Type: Journal    
DOI: 10.3390/v5010321     Document Type: Article

References (48)

1. Kemper, A.R.; Davis, M.M.; Freed, G.L. Expected adverse events in a mass smallpox vaccination campaign. Eff Clin Pract 2002, 5, 84-90.
2. Parrino, J.; Graham, B.S. Smallpox vaccines: Past, present, and future. J. Allergy Clin. Immunol. 2006, 118, 1320-1326.
3. Zurbriggen, S.; Tobler, K.; Abril, C.; Diedrich, S.; Ackermann, M.; Pallansch, M.A.; Metzler, A. Isolation of sabin-like polioviruses from wastewater in a country using inactivated polio vaccine. Appl. Environ. Microbiol. 2008, 74, 5608-5614.
4. Mayr, A.; Munz, E. Changes in the vaccinia virus through continuing passages in chick embryo fibroblast cultures. Zentralbl. Bakteriol. Orig. 1964, 195, 24-35.
5. Meyer, H.; Sutter, G.; Mayr, A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 1991, 72, 1031-1038.
6. Carroll, M.W.; Moss, B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 1997, 238, 198-211.
7. Blanchard, T.J.; Alcami, A.; Andrea, P.; Smith, G.L. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: Implications for use as a human vaccine. J. Gen. Virol. 1998, 79, 1159-1167.
8. Drexler, I.; Heller, K.; Wahren, B.; Erfle, V.; Sutter, G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J. Gen. Virol. 1998, 79, 347-352.
9. Stickl, H.; Hochstein-Mintzel, V.; Mayr, A.; Huber, H.C.; Schäfer, H.; Holzner, A. MVA vaccination against smallpox: Clinical tests with an attenuated live vaccinia virus strain (MVA). Dtsch. Med. Wochenschr. 1974, 99, 2386-2392.
10. Mayr, A. Smallpox vaccination and bioterrorism with pox viruses. Comp. Immunol. Microbiol. Infect. Dis. 2003, 26, 423-430.
11. Webster, D.P.; Dunachie, S.; Vuola, J.M.; Berthoud, T.; Keating, S.; Laidlaw, S.M.; McConkey, S.J.; Poulton, I.; Andrews, L.; Andersen, R.F. et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc. Natl. Acad. Sci. USA 2005, 102, 4836-4841.
12. Cebere, I.; Dorrell, L.; McShane, H.; Simmons, A.; McCormack, S.; Schmidt, C.; Smith, C.; Brooks, M.; Roberts, J.E.; Darwin, S.C.; et al. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 2006, 24, 417-425.
13. Gilbert, S.C.; Moorthy, V.S.; Andrews, L.; Pathan, A.A.; McConkey, S.J.; Vuola, J.M.; Keating, S.M.; Berthoud, T.; Webster, D.; McShane, H.; Hill, A.V.S. Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine 2006, 24, 4554-4561.
14. Sutter, G.; Moss, B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. USA 1992, 89, 10847-10851.
15. Sutter, G.; Wyatt, L.S.; Foley, P.L.; Bennink, J.R.; Moss, B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 1994, 12, 1032-1040.
16. Drillien, R.; Spehner, D.; Hanau, D. Modified vaccinia virus Ankara induces moderate activation of human dendritic cells. J. Gen. Virol. 2004, 85, 2167-2175.
17. Liu, L.; Chavan, R.; Feinberg, M.B. Dendritic cells are preferentially targeted among hematolymphocytes by Modified Vaccinia Virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo. BMC Immunol. 2008, 9, 15.
18. Coulibaly, S.; Brühl, P.; Mayrhofer, J.; Schmid, K.; Gerencer, M.; Falkner, F.G. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection. Virology 2005, 341, 91-101.
19. Hess, R.D.; Weber, F.; Watson, K.; Schmitt, S. Regulatory, biosafety and safety challenges for novel cells as substrates for human vaccines. Vaccine 2012, 30, 2715-2727.
20. Jordan, I.; Vos, A.; Beilfuss, S.; Neubert, A.; Breul, S.; Sandig, V. An avian cell line designed for production of highly attenuated viruses. Vaccine 2009, 27, 748-756.
21. Jordan, I.; Northoff, S.; Thiele, M.; Hartmann, S.; Horn, D.; Höwing, K.; Bernhardt, H.; Oehmke, S.; Von Horsten, H.; Rebeski, D. et al. A chemically defined production process for highly attenuated poxviruses. Biologicals 2011, 39, 50-58.
22. Jordan, I.; Sandig, V. Highly efficient, chemically defined and fully scalable biphasic production of vaccine viruses. BMC Proc. 2011, 5 Suppl 8, O1.
23. Antoine, G.; Scheiflinger, F.; Dorner, F.; Falkner, F.G. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 1998, 244, 365-396.
24. Antoine, G.; Scheiflinger, F.; Dorner, F.; Falkner, F.G. Corrigendum to "The complete genomic sequence of the modified vaccinia Ankara (MVA) strain: Comparison with other orthopoxviruses" [Virology 244 (1998) 365-396]. Virology 2006, 350, 501-502.
25. Goebel, S.J.; Johnson, G.P.; Perkus, M.E.; Davis, S.W.; Winslow, J.P.; Paoletti, E. The complete DNA sequence of vaccinia virus. Virology 1990, 179, 247-266.
26. Jordan, I.; Horn, D.; Oehmke, S.; Leendertz, F.H.; Sandig, V. Cell lines from the Egyptian fruit bat are permissive for modified vaccinia Ankara. Virus Res. 2009, 145, 54-62.
27. Jordan, I.; Munster, V.J.; Sandig, V. Authentication of the R06E fruit bat cell line. Viruses 2012, 4, 889-900.
28. Appleyard, G.; Hapel, A.J.; Boulter, E.A. An antigenic difference between intracellular and extracellular rabbitpox virus. J. Gen. Virol. 1971, 13, 9-17.
29. Plotkin, S.A. Vaccines: The fourth century. Clin. Vaccine Immunol. 2009, 16, 1709-1719.
30. Harrison, S.C.; Alberts, B.; Ehrenfeld, E.; Enquist, L.; Fineberg, H.; McKnight, S.L.; Moss, B.; O'Donnell, M.; Ploegh, H.; Schmid, S.L. et al. Discovery of antivirals against smallpox. Proc. Natl. Acad. Sci. USA 2004, 101, 11178-11192.
31. Moss, B. Poxvirus cell entry: How many proteins does it take? Viruses 2012, 4, 688-707.
32. Byrd, C.M.; Bolken, T.C.; Hruby, D.E. The vaccinia virus I7L gene product is the core protein proteinase. J. Virol. 2002, 76, 8973-8976.
33. Heljasvaara, R.; Rodríguez, D.; Risco, C.; Carrascosa, J.L.; Esteban, M.; Rodríguez, J.R. The major core protein P4a (A10L gene) of vaccinia virus is essential for correct assembly of viral DNA into the nucleoprotein complex to form immature viral particles. J. Virol. 2001, 75, 5778-5795.
34. Kato, S.E.M.; Strahl, A.L.; Moussatche, N.; Condit, R.C. Temperature-sensitive mutants in the vaccinia virus 4b virion structural protein assemble malformed, transcriptionally inactive intracellular mature virions. Virology 2004, 330, 127-146.
35. Yeh, W.W.; Moss, B.; Wolffe, E.J. The vaccinia virus A9L gene encodes a membrane protein required for an early step in virion morphogenesis. J. Virol. 2000, 74, 9701-9711.
36. Husain, M.; Weisberg, A.S.; Moss, B. Resistance of a vaccinia virus A34R deletion mutant to spontaneous rupture of the outer membrane of progeny virions on the surface of infected cells. Virology 2007, 366, 424-432.
37. Blasco, R.; Sisler, J.R.; Moss, B. Dissociation of progeny vaccinia virus from the cell membrane is regulated by a viral envelope glycoprotein: effect of a point mutation in the lectin homology domain of the A34R gene. J. Virol. 1993, 67, 3319-3325.
38. Katz, E.; Wolffe, E.; Moss, B. Identification of second-site mutations that enhance release and spread of vaccinia virus. J. Virol. 2002, 76, 11637-11644.
39. Meiser, A.; Boulanger, D.; Sutter, G.; Krijnse Locker, J. Comparison of virus production in chicken embryo fibroblasts infected with the WR, IHD-J and MVA strains of vaccinia virus: IHD-J is most efficient in trans-Golgi network wrapping and extracellular enveloped virus release. J. Gen. Virol. 2003, 84, 1383-1392.
40. Lohr, V.; Rath, A.; Genzel, Y.; Jordan, I.; Sandig, V.; Reichl, U. New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: studies on growth, metabolism and virus propagation. Vaccine 2009, 27, 4975-4982.
41. Smith, G.L.; Vanderplasschen, A.; Law, M. The formation and function of extracellular enveloped vaccinia virus. J. Gen. Virol. 2002, 83, 2915-2931.
42. Schmidt, F.I.; Bleck, C.K.E.; Mercer, J. Poxvirus host cell entry. Curr. Opin. Virol. 2012, 2, 20-27.
43. Wolf, M.W.; Reichl, U. Downstream processing of cell culture-derived virus particles. Expert Rev. Vaccines 2011, 10, 1451-1475.
44. Schmidt, F.I.; Bleck, C.K.E.; Helenius, A.; Mercer, J. Vaccinia extracellular virions enter cells by macropinocytosis and acid-activated membrane rupture. EMBO J. 2011, 30, 3647-3661.
45. Carter, G.C.; Law, M.; Hollinshead, M.; Smith, G.L. Entry of the vaccinia virus intracellular mature virion and its interactions with glycosaminoglycans. J. Gen. Virol. 2005, 86, 1279-1290.
46. Blasco, R.; Moss, B. Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000-Dalton outer envelope protein. J. Virol. 1991, 65, 5910-5920.
47. Chen, Y.; Honeychurch, K.M.; Yang, G.; Byrd, C.M.; Harver, C.; Hruby, D.E.; Jordan, R. Vaccinia virus p37 interacts with host proteins associated with LE-derived transport vesicle biogenesis. Virol. J. 2009, 6, 44.
48. Vliegen, I.; Yang, G.; Hruby, D.; Jordan, R.; Neyts, J. Deletion of the vaccinia virus F13L gene results in a highly attenuated virus that mounts a protective immune response against subsequent vaccinia virus challenge. Antiviral Res. 2012, 93, 160-166.